Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2004-01-16
2009-11-10
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
C424S130100, C424S133100, C424S141100, C424S153100
Reexamination Certificate
active
07615219
ABSTRACT:
The present invention discloses the use of inhibitors and/or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia).
REFERENCES:
patent: 5486472 (1996-01-01), Suzuki et al.
patent: 6242563 (2001-06-01), Dong
patent: 2002/0182729 (2002-12-01), DiCicco-Bloom et al.
patent: WO 00/05260 (2000-02-01), None
patent: WO 00/23096 (2000-04-01), None
patent: WO 01/23420 (2001-04-01), None
patent: WO 2004/062684 (2004-07-01), None
patent: WO 2004/062684 (2004-07-01), None
Kobayashi et al., Leuk Lymphoma, 1994, 15:45-49.
Bibel et al., Genes and Development, 2000, 14:2919-2937.
Sherwood et al., Endocrine Reviews, 2000, 21:619-670.
Takizawa et al., Experimental Hematology, 2008, 36:897-906.
Dhanjal et al., Blood, 2007, 109:4237-4244.
Freson et al., “PACAP and Its Receptor VPAC1 Regulate Megakaryocyte Maturation: Therapeutic Implications,”Blood111(4):1885-1893 (2008).
Freson et al., “VPAC1 Receptor-Mediated Regulation of Megakaryopoiesis,”Blood104(11):210A (2004). Abstract 735.
Goetzl et al., “Specific Recognition of the Human Neuroendocrine Receptor for Vasoactive Intestinal Peptide by Anti-Peptide Antibodies,”Mol. Cell. Neurosci. 5(2):145-152 (1994).
Communication mailed in connection with EP 07012752.7-1222 on Mar. 28, 2008.
Cox et al.,“VIP Elevates Platelet Cyclic AMP (cAMP) Levels and Inhibits In Vitro Platelet Activation Induced By Platelet-Activating Factor (PAF),”Peptides, 5:325-328 (1984).
Freson et al., “The Pituitary Adenylate Cyclase-Activating Polypeptide Is a Physiological Inhibitor of Platelet Activation,”The Journal of Clinical Investigation, 113:905-912 (2004).
International Search Report (PCT/EP2004/001209).
Written Opinion of ISA (PCT/EP2004/001209).
International Preliminary Report on Patentability (PCT/EP2004/001209).
Ashur-Fabian et al., “Identification of VIP/PACAP Receptors on Rat Astrocytes Using Antisense Oligodeoxynucleotides,”J. Mol. Neurosci. 9(3):211-222 (1997).
Bibel and Barde, “Neurotrophins: Key Regulators of Cell Fate and Cell Shape in the Vertebrate Nervous System,”Genes Dev14(23):2919-2937 (2000).
Busto et al., “Evidence for Multiple Rat VPAC1Receptor States with Different Affinities for Agonists,”Cell Signal. 11(9):691-696 (1999).
Cox et al., “VIP Elevates Platelet Cyclic AMP (cAMP) Levels and Inhibits In Vitro Platelet Activation Induced by Platelet-Activating Factor (PAF),”Peptides5(2):325-328 (1984).
Dhanjal et al., “A Novel Role for PECAM-1 in Megakaryocytokinesis and Recovery of Platelet Counts in Thrombocytopenic Mice,”Blood109(10):4237-4244 (2007).
Freson et al., “VPAC1 Receptor-Mediated Regulation of Megakaryopoiesis,”Blood(ASH Annual Meeting Abstracts) 104:Abstract 735 (2004).
Freson et al., “The Pituitary Adenylate Cyclase-Activating Polypeptide Is a Physiological Inhibitor of Platelet Activation,”J. Clin. Invest. 113(6):905-912 (2004).
Kobayashi et al., “Interleukin 11,”Leuk. Lymphoma15(1-2):45-49 (1994).
Sherwood et al., “The Origin and Function of the Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)/Glucagon Superfamily,”Endocrine Reviews21(6):619-670 (2000).
Shima et al., “Characterization of VIP- and Helodermin-Preferring Receptors on Rat Platelets,”Regulatory Peptides63(2-3):99-103 (1996).
Takizawa et al., “Growth and Maturation of Megakaryocytes Is Regulated by Lnk/Sh2b3 Adaptor Protein Through Crosstalk Between Cytokine- and Integrin-Mediated Signals,”Exp. Hematol. 36(7):897-906 (2008).
Tams et al., “Creation of a Selective Antagonist and Agonist of the Rat VPAC1Receptor Using a Combinatorial Approach with Vasoactive Intestinal Peptide 6-23 as Template,”Mol. Pharmacol. 58(5):1035-1041 (2000).
Freson Kathleen
Hoylaerts Marc
Van Geet Chris
Clark & Elbing LLP
Life Sciences Research Partners VZW
Szperka Michael
LandOfFree
Inhibition of PACAP signalling for the prevention and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of PACAP signalling for the prevention and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of PACAP signalling for the prevention and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4133790